The MDR timeline is not a single date. It is a cascade of milestones, amendments, and transition periods that have shifted multiple times since the regulation was adopted in 2017. For a startup planning its regulatory strategy in 2026, knowing which dates still matter — and which have already passed — is the difference between a realistic plan and a fantasy.
Here is the complete timeline, with every date that affects your decision-making today.
What Are the Key MDR Dates from Adoption Through Application?
April 5, 2017: The European Parliament and the Council adopted Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR).
May 5, 2017: The MDR was published in the Official Journal of the European Union.
May 25, 2017: The MDR entered into force — meaning it became law. However, it did not yet apply. The regulation included a three-year transition period before it would become applicable.
April 24, 2020: The COVID-19 pandemic led to Regulation (EU) 2020/561, which postponed the date of application by one year .
May 26, 2021: The MDR became fully applicable. From this date, all new medical devices placed on the EU market for the first time had to comply with the MDR. The MDD could no longer be used for new device certifications.
This is the date that fundamentally changed the regulatory reality for every MedTech startup. If your device did not already have a valid MDD certificate, you had to go through the MDR path.
What About Devices Already on the Market Under MDD?
This is where the timeline gets complex, and where the 2023 amendment becomes critical.
The original MDR included transition provisions in Article 120 that allowed devices with valid MDD/AIMDD certificates to remain on the market for a limited time. The original deadline was May 26, 2024 — after that, even legacy devices would need MDR certificates.
But a massive problem emerged: the Notified Body capacity was nowhere near sufficient to recertify all existing devices under the MDR by 2024. Thousands of devices faced market withdrawal — not because they were unsafe, but because there were not enough Notified Bodies to process the applications.
The European Commission responded with Regulation (EU) 2023/607, adopted on March 20, 2023 . This amendment extended the transition periods significantly.
What Did Regulation (EU) 2023/607 Change?
The 2023 amendment modified Article 120 of the MDR and introduced staggered deadlines based on device risk class:
For Class III and Class IIb implantable devices: The transition period was extended to December 31, 2027 .
For Class IIb non-implantable, Class IIa, and Class I (sterile or measuring) devices: The transition period was extended to December 31, 2028 .
Critical conditions for using these extended deadlines: 1. The device must continue to comply with the MDD or AIMDD 2. There must be no significant changes in the design or intended purpose 3. The device must not present an unacceptable risk to health or safety 4. The manufacturer must have applied to a Notified Body for MDR conformity assessment before the relevant deadline 5. The Notified Body and the manufacturer must have signed a written agreement for the conformity assessment by September 26, 2024
For startups, these extended deadlines primarily matter if you are acquiring or partnering with a company that has legacy MDD certificates. If you are building a new device from scratch, you go straight to MDR — there is no MDD transition available for new products.
What Is the Current Status of EUDAMED?
EUDAMED — the European Database on Medical Devices — has its own troubled timeline:
Original plan: EUDAMED was supposed to be fully functional by May 26, 2020 (later May 26, 2021). It was not.
Reality: EUDAMED has been deployed module by module. The actor registration module has been available since December 2020. The UDI/Device registration module and the Notified Body and certificates module followed .
Current status (2026): EUDAMED is partially operational but not yet fully functional. The Commission has not yet issued the notice confirming full functionality, which means certain EUDAMED-dependent provisions of the MDR have not yet taken effect .
For startups, the practical impact is that some registration and reporting requirements are handled through national systems rather than EUDAMED. Monitor the Commission's announcements on this — when full EUDAMED functionality is confirmed, new obligations will activate with a defined transition period.
What Are the UDI Implementation Deadlines?
The UDI (Unique Device Identification) system has staggered implementation timelines based on device class:
- Class III and implantable devices: UDI requirements applied from May 26, 2021
- Class IIa and Class IIb devices: UDI requirements applied from May 26, 2023
- Class I devices: UDI requirements applied from May 26, 2025
These dates affect your labeling, packaging, and data management systems. If you are launching a new device in 2026, UDI compliance is required from day one regardless of your class.
How Does This Timeline Affect a Startup's Planning in 2026?
Here is the practical framework for a startup building a new medical device today:
Month 0–3: Regulatory strategy phase. Determine your intended purpose, classify your device, identify your conformity assessment route, and select a Notified Body. Start the Notified Body application process as early as possible — wait times are real and they do not shorten because your deadline is approaching.
Month 3–12: Development and documentation phase. Build your QMS, develop your technical documentation, conduct risk management activities, plan your clinical evaluation strategy. These activities should run in parallel with product development, not after it.
Month 12–18: Clinical evidence generation. Depending on your device class and clinical evaluation strategy, this may involve literature reviews, bench testing, clinical investigations, or a combination. For higher-risk devices, this phase can extend significantly.
Month 18–24: Notified Body audit. Submit your documentation, undergo Stage 1 and Stage 2 audits, respond to any non-conformities, and receive your certificate.
Month 24–30: CE marking and market launch. Finalize your Declaration of Conformity, apply your CE marking, register in the relevant databases, and launch.
These are rough estimates — every device is different. A Class I non-sterile device can move much faster. A Class III implantable can take significantly longer. But the overall message is clear: from concept to market under the MDR, plan for 18 to 36 months at minimum.
The founders who fail are not those who find the timeline too long. They are those who discover the timeline too late — after they have made promises to investors, set launch dates based on wishful thinking, or committed resources to a development path that ignores regulatory reality.
What Dates Should You Monitor Going Forward?
Several MDR-related deadlines and developments remain in flux:
- EUDAMED full functionality notice — when issued, it will trigger new obligations with a defined transition period
- Common specifications under Article 9 — the Commission can adopt common specifications for any device category at any time, creating new requirements
- Implementing acts and delegated acts — the Commission continues to issue supplementary rules under the MDR
- Harmonized standards — the list of harmonized standards under the MDR is updated periodically, and new standards can change what is expected for demonstrating conformity
- MDCG guidance documents — not legally binding but practically influential, these are updated regularly and shape how Notified Bodies interpret the regulation
The MDR is a living regulatory system. The text is fixed, but its practical application evolves through guidance, standards, and implementing acts. Staying current is not optional — it is part of the ongoing obligation of being a manufacturer.
For a deep dive into how to actually read and work with the MDR text, see our next post: How to Read the MDR: A Founder's Guide to Navigating 175 Articles and 17 Annexes.